Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352501 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 | |
| SCHEMBL5356183 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 | |
| SCHEMBL5351850 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 | |
| SCHEMBL5351214 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 | |
| SCHEMBL5349839 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 | |
| SCHEMBL5356343 | 0.75 | CTSD (0.37) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 | |
| SCHEMBL5352497 | 0.74 | CACNA1B (0.58) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 | |
| SCHEMBL5356175 | 0.74 | CACNA1B (0.58) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 | |
| SCHEMBL5348996 | 0.74 | CACNA1B (0.58) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 | |
| SCHEMBL7355228 | 0.74 | METAP2 (0.68) | SMN1; SMN2NPC1RAB9ACPB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013725-A1 | Amino acid derivatives | CACNA1B, SCN1A, SCN2A | SMN1; SMN2 297/4885NPC1 534/4885RAB9A 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.